Support from Harrington Discovery Institute at University Hospitals Helped Advance Heart Attack Drug into Clinical Trials

Contributed by: PR Newswire

Tags

Harrington-ins.-trial

More Like This

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

PR Newswire associated0

Emboline Announces Positive Pivotal PROTECT H2H Trial Results for Emboliner® Presented as a Late-Breaking Clinical Trial at ACC 2026

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership

PR Newswire associated0

Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease

From left: Dr. Kitazawa, Dr. Hattori, and Dr. Igawa

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors

CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology